Medical Care Facilities Industry | Healthcare Sector | - CEO | XSHE Exchange | CNE000000016 ISIN |
China Country | 8,173 Employees | - Last Dividend | 19 May 2016 Last Split | - IPO Date |
Xi'an International Medical Investment Company Limited is a prominent provider of healthcare services founded in 1986, originally known as Xi'an Kaiyuan Investment Group Co., Ltd. The company underwent a rebranding phase in January 2015, adopting its current name to reflect its expanded focus on the international medical sector. Located in Xi'an, China, it has steadily grown to operate a variety of healthcare facilities, including hospitals and medical centers. Besides healthcare services, Xi'an International Medical Investment has diversified its operations into insurance broking, tourism, and pharmaceutical production, positioning itself as a multifaceted enterprise within the healthcare and related industries.
At its core, Xi'an International Medical Investment operates hospitals and medical centers, offering a broad spectrum of medical services to meet the health needs of the communities it serves. This includes both inpatient and outpatient services, specialized care, and general medical services.
The company extends its services into the insurance sector by offering insurance broking services. This involves advising clients on various insurance products, helping them choose plans that best suit their needs, whether related to health, life, or property insurance.
Recognizing the interconnection between healthcare and well-being, Xi'an International Medical Investment has ventured into the tourism industry. This includes the development of medical tourism, where individuals travel to receive medical treatments combined with the opportunity to visit attractions in Xi'an and its surroundings.
The diversification of its business model includes the production of pharmaceuticals. This not only complements its primary health services by ensuring the availability of quality medicines but also allows it to engage in research and development of new drugs, contributing to advancements in medical treatments and health outcomes.